Back to Discover

MNKD · Biotech · Nasdaq · As of 21 Nov 2026

Mannkind Corp stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
52

Neutral · 52 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

Very high

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Too few of the required measures on file

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Too few of the required measures on file

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Watch

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Balanced

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.

Discovery Gap: Very high (84/100) · Gap confidence 70/100

Discovery gap

Documented progress is running well ahead of market attention.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: +3Moved up +3 on new evidence.
Window31 Oct 2026 → 21 Nov 2026
Momentum+3Lifted the score this month.

Evidence timeline

What changed — last 90 days

As of 14 Nov 2026
  1. The company reported Q3 2026 revenues grew 24% year-over-year to $101.9M, with commercial product revenue doubling to $45M.

    Results · 8-K filed 5 Nov →

  2. The company filed its quarterly report for the period ending September 30, 2026.

    Quarterly/annual report · 10-Q filed 5 Nov →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Fri 26 Feb · expected 10-K

    Last year filed 26 Feb 2026.

  3. Thu 6 May · expected 10-Q

    Last year filed 6 May 2026.

  4. Filed and other evidence
  5. Thu 5 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenues grew 24% YoY to $101.9M, driven by Furoscix ReadyFlow rapid adoption (75% of shipments) and Afrezza pediatric launch success. Commercial product revenue doubled to $45M. Pipeline advanced with positive Phase 1b nintedanib DPI results.

    Gap Very high · 83 → Very high · 86

    Progress is running ahead of attention.

  6. Thu 5 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 83 → Very high · 86

    Progress is running ahead of attention.

  7. Fri 21 Aug · 8-K

    8-K · Item 8.01 — Other events

  8. Wed 5 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  9. Wed 5 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  10. Fri 24 Jul · 8-K

    8-K · Items 3.02, 8.01 — Unregistered sale of shares

  11. Tue 2 Jun · 8-K

    8-K · Item 8.01 — Other events

  12. Fri 29 May · FDA

    [FDA supplemental_efficacy_approval] MANNKIND CORP — AFREZZA (BLA022472/29) — Supplemental efficacy approval (new indication / label expansion)

  13. Thu 28 May · 8-K

    8-K · Item 8.01 — Other events

  14. Fri 22 May · 8-K

    Current report (8-K)

  15. Wed 6 May · 8-K

    8-K · Item 2.02 — Results of operations

  16. Wed 6 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  17. Thu 26 Feb · 8-K

    8-K · Item 2.02 — Results of operations

  18. Thu 26 Feb · 10-K

    Annual report (10-K), FY2025

  19. Fri 23 Jan · FDA

    [FDA supplemental_efficacy_approval] MANNKIND CORP — AFREZZA (BLA022472/27) — Supplemental efficacy approval (new indication / label expansion)

Earlier →

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast. Small grey outline: other evidence on record, such as an FDA decision.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.